Initiation of Phase IIa clinical trial of ATL1102 in patients with multiple sclerosis; Approval for Proof of Concept clinical trial of ATL1101 in patients with psoriasis; In contrast to gene therapy antisense drugs do not alter human genes or have any effect on human genetic information. This review outlines the basic concept of the antisense technology, its development and recent potential therapeutic applications. The various protein targets and antisense agents in clinical trials in cancer treatment are as follows:. Phase I/II studies, evaluating the combination therapy of ISIS 3521 and chemotherapeutic agents, were initiated in patients with stage III B or IV Non-small Cell Lung Carcinoma (NSCLC) (Villalona-Calero et al. Agreement gives CompleGen access to a large compound chemical library. October 27, 2004 2004 OCT 27 – (NewsRx. Bariatric surgery study finds typical patient still obese 3 years after surgery. CombinatoRx and partner initiate brain cancer collaboration. Company seeks to begin proof of concept study for ATL1101 in psoriasis.
Calzada, Polynovo Recruit 20-Patient Novosorb Wound Trial; Circadian Nears Completion Of Phase I VGX-100 Tumor Trial; Graham Edwards, Montoya Take 5. Benitec Claims Proof-Of-Concept For ddRNAi Pain Compound; Euro Patent For Novogen, MEI Pharma ME-344 For Cancer; Nusep Installs 1st Prime Unit In Singapore; Isonea Applies For US Sonosentry OTC Sales; Consegna Breatheassist Meets Triple A Sales Due Diligence; Baillie Gifford Takes 9. Collaborate For Cancer Research; European Patent For Antisense ATL1101;
Biotech Daily, Daily News On Asx-listed Biotechnology Companies